Exemplified by the success of immune checkpoint inhibition using antibodies against PD-1 and PD-L1 and chimeric antigen receptor-T (CAR-T) cell therapies, cancer immunotherapy has achieved remarkably effective and durable responses in a subset of patients with different cancer types. Here, CD274 is linked to cancer.